Skip to main content
Fig. 1 | Journal of Experimental & Clinical Cancer Research

Fig. 1

From: Co-administration of 20(S)-protopanaxatriol (g-PPT) and EGFR-TKI overcomes EGFR-TKI resistance by decreasing SCD1 induced lipid accumulation in non-small cell lung cancer

Fig. 1

LD accumulation and fatty acid metabolism increase during EGFR-TKI treatment (a) Basal LD content of both tumors and adjacent tissues were assessed by Oil Red O staining between two groups of patients who received EGFR-TKI treatment and patients who did not. b Left panel, basal LD content of different mutation status cell lines assessed by Nile red staining. Right panel, quantitation of Nile red staining of each cell lines. Lipid accumulation was evaluated by measuring Nile red fluorescence by flow cytometry; data are expressed as the percentage of level found in control cells treated only by the vehicle (HCC827GR) and are the means ± SD of at least 3 independent experiments. *p < 0.05, **p < 0.01, when compared to control cells. c Left panel, immunohistochemical staining for SCD1 protein in paired patient tumor tissues before and after TKI treatment. Brown color in cancer cells denotes positive staining. Representative images of SCD1 expression in NSCLC specimens from three representative patients are shown. Right panel, the immunohistochemical score for SCD1 was significantly different between the pre- and post-Gefitinib treatment specimens. p values were determined by unpaired t test. ***p < 0.001. d Boxplots showing the expression level of SCD1/FASN/PLIN in the GSE83666 dataset. e Up panel, basal LD content assessed by Nile red staining after 48 h of treatment with Gefitinib. Down panel, quantitation of Nile red staining of each cell lines. The quantitative method is the same as above, the vehicle is (HCC827GR without treatment) f Boxplots showing the expression level of PLIN/SCD1 in HCC827/HCC827ER after 12 h exposed in Erlotinib in the microdissected of GSE38310. g Left panel, basal LD content assessed by Nile red staining after 12 h of treatment with Gefitinib. Right panel, quantitation of Nile red staining by flow cytometry; the quantitative method is the same as above, and the vehicle is (HCC827GR DMSO-12 h).

Back to article page